Omalizumab – an effective and safe treatment of therapy-resistant chronic spontaneous urticaria

Authors


  • CsU patients showed marked improvement in symptoms and reduction of concomitant medication early after the start of omalizumab therapy. Omalizumab is an important therapeutic option in patients with severe and therapy-resistant csU.

Department of Dermatology
Universitätsmedizin Mainz
Langenbeckstr. 1
55131 Mainz
Tel.: 06131-172942
Fax: 06131-175594
E-mail: petra.staubach@unimedizin-mainz.de

No abstract is available for this article.

Ancillary